Online citations, reference lists, and bibliographies.
← Back to Search

Tumor Microenvironment: Challenges And Opportunities In Targeting Metastasis Of Triple Negative Breast Cancer.

K. Deepak, R. K. Vempati, G. P. Nagaraju, V. Dasari, S. Nagini, D. N. Rao, Rama Rao Malla
Published 2020 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Triple negative breast cancer (TNBC) is most aggressive subtype of breast cancers with high probability of metastasis as well as lack of specific targets and targeted therapeutics. TNBC is characterized with unique tumor microenvironment (TME), which differs from other subtypes. TME is associated with induction of proliferation, angiogenesis, inhibition of apoptosis and immune system suppression, and drug resistance. Exosomes are promising nanovesicles, which orchestrate the TME by communicating with different cells within TME. The components of TME including transformed ECM, soluble factors, immune suppressive cells, epigenetic modifications and re-programmed fibroblasts together hamper antitumor response and helps progression and metastasis of TNBCs. Therefore, TME could be a therapeutic target of TNBC. The current review presents latest updates on the role of exosomes in modulation of TME, approaches for targeting TME and combination of immune checkpoint inhibitors and target chemotherapeutics. Finally, we also discussed various phytochemicals that alter genetic, transcriptomic and proteomic profiles of TME along with current challenges and future implications. Thus, as TME is associated with the hallmarks of TNBC, the understanding of the impact of different components can improve the clinical benefits of TNBC patients.
This paper references
10.3389/fimmu.2019.00757
Tumor-Stroma-Inflammation Networks Promote Pro-metastatic Chemokines and Aggressiveness Characteristics in Triple-Negative Breast Cancer
Yulia Liubomirski (2019)
10.1186/s13148-018-0512-1
DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer
Varun Sasidharan Nair (2018)
10.1038/modpathol.2010.205
β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation
F. Geyer (2011)
10.3389/fimmu.2018.01288
Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses
F. Hossain (2018)
10.1189/jlb.1VMR1216-505R
The mazy case of Notch and immunoregulatory cells
P. Grazioli (2017)
10.3892/OL.2011.460
Glyceollins as novel targeted therapeutic for the treatment of triple-negative breast cancer.
L. Rhodes (2012)
10.3390/ijms18020405
Tumor Microenvironment, a Paradigm in Hepatocellular Carcinoma Progression and Therapy
M. Tahmasebi Birgani (2017)
10.3389/fimmu.2019.00804
Notch-Mediated Tumor-Stroma-Inflammation Networks Promote Invasive Properties and CXCL8 Expression in Triple-Negative Breast Cancer
Yulia Liubomirski (2019)
10.1186/2051-1426-1-S1-O22
Towards an immunoscore for triple negative breast cancer (TNBC): lymphocytic infiltrate predicts outcome
S. Adams (2013)
10.3389/fimmu.2018.00101
Regulation of CD8+ T Cells and Antitumor Immunity by Notch Signaling
S. Tsukumo (2018)
10.1016/j.canlet.2018.06.034
Targeting cancer stem cells with dietary phytochemical - Repositioned drug combinations
M. Chan (2018)
10.1038/s41573-019-0032-5
Targeting metabolism to regulate immune responses in autoimmunity and cancer
C. H. Patel (2019)
10.3390/ijms18061178
Dietary Intervention by Phytochemicals and Their Role in Modulating Coding and Non-Coding Genes in Cancer
Liviuţa Budişan (2017)
10.1200/JCO.2009.22.4725
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.
D. Silver (2010)
10.1364/BOE.9.002543
Erratum: Methods for detecting host genetic modifiers of tumor vascular function using dynamic near-infrared fluorescence imaging: errata.
Jaidip M Jagtap (2018)
10.1158/1078-0432.CCR-06-3045
Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence
R. Dent (2007)
10.21037/tcr.2017.10.51
TIC10/ONC201-a potential therapeutic in glioblastoma.
G. Karpel-Massler (2017)
10.1128/MCB.23.5.1817-1831.2003
A Mutant Receptor Tyrosine Phosphatase, CD148, Causes Defects in Vascular Development
T. Takahashi (2003)
10.1158/0008-5472.CAN-15-1640-T
Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population.
N. Bhola (2016)
10.1186/bcr2933
The non-protein coding breast cancer susceptibility locus Mcs5a acts in a non-mammary cell-autonomous fashion through the immune system and modulates T-cell homeostasis and functions
B. Smits (2011)
10.1016/j.semcancer.2019.07.005
Horizons of nanotechnology applications in female specific cancers.
B. Rajitha (2019)
10.1002/cam4.833
The hedgehog pathway in triple‐negative breast cancer
Joyce G. Habib (2016)
10.1158/0008-5472.CAN-07-5644
Subtypes of breast cancer show preferential site of relapse.
M. Smid (2008)
10.1186/bcr2944
Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study
H. Sihto (2011)
10.1016/j.ccr.2012.02.022
Accessories to the crime: functions of cells recruited to the tumor microenvironment.
D. Hanahan (2012)
10.1038/cr.2011.22
Regulation of chromatin by histone modifications
Andrew J. Bannister (2011)
10.1155/2014/351959
Tumor Microenvironment: A New Treatment Target for Cancer
Ming-Ju Tsai (2014)
10.1016/j.canlet.2019.06.012
Tumor-derived extracellular vesicles in breast cancer: from bench to bedside.
Hong-xia Wang (2019)
10.3390/cancers11070938
Mir526b and Mir655 Promote Tumour Associated Angiogenesis and Lymphangiogenesis in Breast Cancer
S. Hunter (2019)
10.1001/jamaoncol.2016.5281
Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab
R. Basho (2017)
10.3390/cancers11060771
A Review of the Role of Wnt in Cancer Immunomodulation
W. Goldsberry (2019)
10.1016/j.canlet.2015.07.039
Tumor microenvironment: Sanctuary of the devil.
Lanlan Hui (2015)
10.3389/fonc.2018.00367
The Tumor Vascular Endothelium as Decision Maker in Cancer Therapy
D. Klein (2018)
10.1126/science.aar6711
CAR T cell immunotherapy for human cancer
C. June (2018)
10.1016/j.ejmech.2012.12.053
Characterization of a selective CaMKII peptide inhibitor.
I. Gomez-Monterrey (2013)
10.1016/j.cell.2015.08.016
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chih-Hao Chang (2015)
10.1016/j.breast.2013.07.010
The metastatic microenvironment of breast cancer: clinical implications.
R. Coleman (2013)
10.1186/1479-5876-9-9
Human saliva, plasma and breast milk exosomes contain RNA: uptake by macrophages
Cecilia Lässer (2010)
10.1038/s12276-018-0191-1
Immune checkpoint inhibitors: recent progress and potential biomarkers
Pramod Darvin (2018)
10.1006/GENO.2001.6562
Three loci modify growth of a transgene-induced mammary tumor: suppression of proliferation associated with decreased microvessel density.
T. L. Le Voyer (2001)
10.1038/nrclinonc.2015.215
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
P. Savas (2016)
10.1038/s41419-019-1512-6
Inhibition of USP2 eliminates cancer stem cells and enhances TNBC responsiveness to chemotherapy
Jiabei He (2019)
10.1186/1479-5876-10-1
The immune score as a new possible approach for the classification of cancer
J. Galon (2011)
10.1016/j.cell.2011.02.013
Hallmarks of Cancer: The Next Generation
D. Hanahan (2011)
10.1016/j.trecan.2018.04.003
Genetic Modifiers of the Breast Tumor Microenvironment.
M. J. Flister (2018)
10.1016/bs.acr.2016.08.003
MicroRNAs and Their Impact on Breast Cancer, the Tumor Microenvironment, and Disparities.
A. Evans-Knowell (2017)
10.1002/cncy.21951
Biomarkers for immune checkpoint inhibitors: The importance of tumor topography and the challenges to cytopathology
D. P. Clark (2018)
10.1038/nrc3239
The blockade of immune checkpoints in cancer immunotherapy
D. Pardoll (2012)
10.1155/2015/649161
The Role of Extracellular Vesicles: An Epigenetic View of the Cancer Microenvironment
Zhongrun Qian (2015)
10.1002/cam4.1722
Checkpoint blockade‐based immunotherapy in the context of tumor microenvironment: Opportunities and challenges
J. Duan (2018)
10.1200/JCO.2010.30.5425
Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction.
B. Mlecnik (2011)
10.1038/labinvest.2008.31
The fibromatosis signature defines a robust stromal response in breast carcinoma
A. Beck (2008)
10.1016/j.cell.2016.11.005
The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity
T. Moroishi (2016)
10.1007/s11010-011-0985-0
3,3′-Diindolylmethane inhibits breast cancer cell growth via miR-21-mediated Cdc25A degradation
Yucui Jin (2011)
10.1016/j.stemcr.2013.11.009
Breast Cancer Stem Cells Transition between Epithelial and Mesenchymal States Reflective of their Normal Counterparts
S. Liu (2014)
10.1016/j.molonc.2014.12.010
Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: Novel anti‐tumor mechanisms of Cannabidiol in breast cancer
Mohamad Elbaz (2015)
10.1158/1078-0432.CCR-15-1348
RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer
Y. Liu (2016)
10.1186/s12943-018-0800-6
Targeting tumour microenvironment by tyrosine kinase inhibitor
Hor-Yue Tan (2018)
10.1016/j.jnutbio.2015.08.005
Anthocyanin-containing purple-fleshed potatoes suppress colon tumorigenesis via elimination of colon cancer stem cells.
Venkata Charepalli (2015)
10.1158/1535-7163.MCT-13-0903
EW-7197, a Novel ALK-5 Kinase Inhibitor, Potently Inhibits Breast to Lung Metastasis
J. Son (2014)
10.4049/jimmunol.1201892
Tumor-Infiltrating γδ T Lymphocytes Predict Clinical Outcome in Human Breast Cancer
Chunling Ma (2012)
10.1007/s10549-019-05156-5
Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women
Tess O’Meara (2019)
10.2217/EPI-2016-0110
Epigenetic control of the tumor microenvironment.
D. Marks (2016)
10.1097/01.QAI.0000557969.79559.A8
E-103 Inflammation-driven networks in the regulation of breast cancer progression
A. Ben-Baruch (2019)
10.2353/ajpath.2010.090777
Contribution of MyD88 to the tumor exosome-mediated induction of myeloid derived suppressor cells.
Yuelong Liu (2010)
10.1111/bph.13211
Therapeutic targets of triple‐negative breast cancer: a review
V. Jamdade (2015)
10.1016/j.bbalip.2013.10.004
Exosomes as new vesicular lipid transporters involved in cell-cell communication and various pathophysiologies.
M. Record (2014)
10.1038/srep10194
Inhibition of STAT3, FAK and Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer
R. Thakur (2015)
10.3892/OL.2011.357
Overexpression of Hedgehog signaling molecules and its involvement in triple-negative breast cancer.
Y. Tao (2011)
10.1016/j.bbacli.2015.03.003
The fate of chemoresistance in triple negative breast cancer (TNBC)
E. A. O'Reilly (2015)
10.1158/1535-7163.MCT-17-0098
Modeling Therapy Resistance in BRCA1/2-Mutant Cancers
Amy Dréan (2017)
10.18632/oncotarget.19194
EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release.
K. J. Suh (2017)
10.1158/1541-7786.MCR-11-0154
Direct Effect of Rituximab in B-Cell–Derived Lymphoid Neoplasias: Mechanism, Regulation, and Perspectives
C. Bezombes (2011)
10.1007/s40291-019-00401-5
S1PR1 as a Novel Promising Therapeutic Target in Cancer Therapy
N. Rostami (2019)
10.1371/journal.pone.0002888
Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal Transition
A. Morel (2008)
10.1007/s00109-011-0855-y
Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis
C. C. Wong (2011)
10.1016/j.jprot.2018.09.005
2'-Hydroxyflavanone induced changes in the proteomic profile of breast cancer cells.
L. Nagaprashantha (2019)
10.1016/j.breast.2017.06.023
Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC).
L. Wein (2017)
10.15252/embr.201439246
The extracellular matrix modulates the hallmarks of cancer
M. Pickup (2014)
10.1016/J.JFF.2016.06.007
Indian gooseberry (Emblica officinalis Gaertn.) suppresses cell proliferation and induces apoptosis in human colon cancer stem cells independent of p53 status via suppression of c-Myc and cyclin D1
Ramakrishna Vadde (2016)
10.1016/j.ejphar.2015.08.032
Herbacetin inhibits inducible nitric oxide synthase via JNK and nuclear factor-κB in LPS-stimulated RAW264.7 cells.
L. Li (2015)
10.2174/1389200220666191007153238
Curcumin - A Novel Therapeutic Agent In The Prevention Of Colorectal Cancer.
M. Gupta (2019)
10.1073/pnas.1410041111
Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis
T. Wang (2014)
10.1016/J.CEB.2007.02.007
Wnt/β-catenin signaling in cancer stemness and malignant behavior
R. Fodde (2007)
10.18632/oncotarget.10491
Induction of HOXA9 expression in three-dimensional organotypic culture of the Claudin-low breast cancer cells
M. Li (2016)
10.1016/j.clbc.2016.05.006
Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial.
D. Yardley (2016)
10.2217/bmm-2017-0398
Cancer stem cells in triple-negative breast cancer: a potential target and prognostic marker.
C. O’Conor (2018)
10.18632/oncotarget.14247
Visualization of exosome-mediated miR-210 transfer from hypoxic tumor cells
Kyung Oh Jung (2017)
10.1186/1868-7083-6-20
Expression profiling of DNA methylation-mediated epigenetic gene-silencing factors in breast cancer
Swayamsiddha Kar (2014)
10.1016/j.clim.2018.02.013
Epigenetic interplay between immune, stromal and cancer cells in the tumor microenvironment.
A. Garcia-Gomez (2018)
10.1093/carcin/bgx037
Emerging evidence for the role of differential tumor microenvironment in breast cancer racial disparity: a closer look at the surroundings
S. Deshmukh (2017)
10.3390/cancers10120483
Sensitization of Drug Resistant Cancer Cells: A Matter of Combination Therapy
Meghan Leary (2018)
10.1200/JCO.2009.25.9820
Metastatic behavior of breast cancer subtypes.
H. Kennecke (2010)
10.1172/JCI96313
Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers
T. Gruosso (2019)
10.1073/pnas.1222251110
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer
S. Loi (2013)
10.1002/stem.1752
STAT3 Signaling Is Activated Preferentially in Tumor‐Initiating Cells in Claudin‐Low Models of Human Breast Cancer
W. Wei (2014)
10.1158/1538-7445.AM2017-1043
Abstract 1043: CSF-1R inhibitor prevented pre-metastatic lung niches in metastatic mammary tumor
T. Borin (2017)
10.1172/JCI81135
The biology and function of exosomes in cancer.
R. Kalluri (2016)
10.1172/JCI44745
The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors.
Lauren L C Marotta (2011)
10.4161/cbt.29183
Combination therapy with anti-DR5 antibody and tamoxifen for triple negative breast cancer
H. Kim (2014)
10.1016/j.intimp.2018.06.005
Phytochemicals inhibit the immunosuppressive functions of myeloid‐derived suppressor cells (MDSC): Impact on cancer and age‐related chronic inflammatory disorders
A. Salminen (2018)
10.1016/j.cellimm.2018.01.014
IFN-γ and tumor gangliosides: Implications for the tumor microenvironment.
Barbara Dillinger (2018)
10.1002/1878-0261.12167
Dual inhibition of Wnt and Yes‐associated protein signaling retards the growth of triple‐negative breast cancer in both mesenchymal and epithelial states
Andrew Sulaiman (2018)
10.1007/s12282-016-0698-z
Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication
S. Burugu (2016)
10.1158/0008-5472.CAN-06-4806
The adaptive immunologic microenvironment in colorectal cancer: a novel perspective.
J. Galon (2007)
10.3389/fonc.2017.00298
Reactive Astrocytes in Brain Metastasis
David Wasilewski (2017)
10.1038/ncomms7692
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
N. Patsoukis (2015)
10.1016/j.cell.2015.08.012
Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses
Ping-Chih Ho (2015)
10.1016/j.canlet.2014.05.006
An novel inhibitor of TGF-β type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial-mesenchymal transition.
Chul-yong Park (2014)
10.1155/2015/649263
Triphala Extract Suppresses Proliferation and Induces Apoptosis in Human Colon Cancer Stem Cells via Suppressing c-Myc/Cyclin D1 and Elevation of Bax/Bcl-2 Ratio
Ramakrishna Vadde (2015)
10.1016/j.addr.2012.07.002
Exosomes are endogenous nanoparticles that can deliver biological information between cells.
D. Sun (2013)
10.1158/1078-0432.CCR-18-3524
Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer
Yi Xiao (2019)
10.1200/jco.2013.31.26_suppl.31
Calculation of an immunoscore based on extensive flow cytometry analysis of PBMCs from metastatic breast cancer patients treated with docetaxel alone or in combination with vaccine.
R. Donahue (2013)
10.3760/cma.j.issn.0253-3766.2019.06.001
[Role of PD-1/PD-L1 in microenvironment of breast cancer].
P. Ji (2019)
10.3892/ol.2017.6959
CD44+/CD24− phenotype predicts a poor prognosis in triple-negative breast cancer
Hui Wang (2017)
10.3390/ijms17081296
Binding and Fusion of Extracellular Vesicles to the Plasma Membrane of Their Cell Targets
Ilaria Prada (2016)
10.1371/journal.pone.0121281
CoREST1 Promotes Tumor Formation and Tumor Stroma Interactions in a Mouse Model of Breast Cancer
S. Mazumdar (2015)
10.18632/oncotarget.16684
Exosome: emerging biomarker in breast cancer
Y. Jia (2017)
10.1007/s10565-018-09458-0
Interaction of EZH2 and P65 is involved in the arsenic trioxide-induced anti-angiogenesis in human triple-negative breast cancer cells
F. Jiang (2019)
10.4161/cam.20377
The role of the myofibroblast in tumor stroma remodeling
Marcela Otranto (2012)
10.1021/acsnano.7b01522
Quercetin Remodels the Tumor Microenvironment To Improve the Permeation, Retention, and Antitumor Effects of Nanoparticles.
K. Hu (2017)
10.3892/or.2016.4547
A matrix metalloproteinase inhibitor enhances anti-cytotoxic T lymphocyte antigen-4 antibody immunotherapy in breast cancer by reprogramming the tumor microenvironment
M. Li (2016)
10.1016/j.ccell.2016.10.009
Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis.
A. Becker (2016)
10.1016/j.cytogfr.2017.04.003
Dysfunctional T cell metabolism in the tumor microenvironment.
Kathryn E. Beckermann (2017)
10.1016/j.tips.2018.03.008
Targeting Wnt/β-Catenin Signaling for Cancer Immunotherapy.
Bojun Wang (2018)
10.2217/14796694.1.6.787
The role of Wnt signaling in cancer and stem cells.
N. Reguart (2005)
Understanding and treating triple-negative breast cancer.
C. Anders (2008)
10.1016/j.critrevonc.2017.02.025
Role of hypoxia-inducible factors (HIF) in the maintenance of stemness and malignancy of colorectal cancer.
Ramakrishna Vadde (2017)
10.1002/eji.201848058
Targeting the tumor microenvironment and T cell metabolism for effective cancer immunotherapy
H. Hope (2019)
10.1158/0008-5472.CAN-13-3212
CXM: a new tool for mapping breast cancer risk in the tumor microenvironment.
M. J. Flister (2014)
10.1053/j.seminoncol.2017.06.006
Current challenges in the management of breast cancer brain metastases.
C. C. O'Sullivan (2017)
10.1038/SJ.BJC.6605143
Type I collagen inhibits differentiation and promotes a stem cell-like phenotype in human colorectal carcinoma cells.
Kirkland Sc (2009)
10.1158/1078-0432.CCR-13-3173
Molecular Pathways: Linking Tumor Microenvironment to Epithelial–Mesenchymal Transition in Metastasis
Hae-Yun Jung (2014)
10.1007/s00281-018-0689-6
Tumor-derived exosomes, microRNAs, and cancer immune suppression
M. Graner (2018)
10.2967/jnumed.117.198952
In Vivo Imaging of Pro- and Antitumoral Cellular Components of the Tumor Microenvironment
Anne Helfen (2018)
10.1016/j.cell.2008.03.027
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Sendurai A Mani (2008)
10.1002/cncr.28914
Subtyping of triple‐negative breast cancer: Implications for therapy
V. Abramson (2015)
10.1007/s12032-009-9344-3
Curcumin reduces the expression of Bcl-2 by upregulating miR-15a and miR-16 in MCF-7 cells
J. Yang (2010)
10.1038/s41467-019-10424-5
CaMKK2 in myeloid cells is a key regulator of the immune-suppressive microenvironment in breast cancer
L. Racioppi (2019)
10.1093/annonc/mdu112
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.
S. Loi (2014)
10.1080/15384047.2015.1026481
A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer
S. Cowherd (2015)
A perspective on anti-EGFR therapies targeting triple-negative breast cancer.
K. Nakai (2016)
10.1016/j.bbrc.2017.06.117
IL-1β induced methylation of the estrogen receptor ERα gene correlates with EMT and chemoresistance in breast cancer cells.
A. M. Jiménez-Garduño (2017)
10.1002/jcp.22697
Collagen I regulates the self‐renewal of mouse embryonic stem cells through α2β1 integrin‐ and DDR1‐dependent Bmi‐1
Han Na Suh (2011)
10.1016/j.ccell.2014.09.005
Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis.
S. Melo (2014)
10.1038/s41389-017-0011-9
The hypoxic tumour microenvironment
V. Petrova (2018)
10.1038/oncsis.2017.88
DNA methylation signal has a major role in the response of human breast cancer cells to the microenvironment
P. Mathot (2017)
10.1038/s41598-017-17913-x
LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer
T. Boulding (2018)
10.1007/s10555-007-9055-1
Hypoxia in cancer: significance and impact on clinical outcome
P. Vaupel (2007)
10.1039/C8RA08924H
A chemotherapeutic approach targeting the acidic tumor microenvironment: combination of a proton pump inhibitor and paclitaxel for statistically optimized nanotherapeutics
S. Bhattacharya (2019)
10.1007/s10549-018-4907-7
Pro-inflammatory cytokines and growth factors in human milk: an exploratory analysis of racial differences to inform breast cancer etiology
J. Murphy (2018)
10.1146/annurev-immunol-032712-095956
Metabolic regulation of T lymphocytes.
Nancie J. MacIver (2013)
10.1038/nature10694
Interactions between cancer stem cells and their niche govern metastatic colonization
Ilaria Malanchi (2012)
10.1002/hep.24504
Intercellular nanovesicle‐mediated microRNA transfer: A mechanism of environmental modulation of hepatocellular cancer cell growth
Takayuki Kogure (2011)
10.1073/pnas.1816410116
JAK/STAT inhibition in macrophages promotes therapeutic resistance by inducing expression of protumorigenic factors
E. Irey (2019)
10.1016/j.biocel.2012.08.007
Exosomes: new players in cell-cell communication.
C. Bang (2012)
10.1016/j.stem.2018.12.009
Cancer Stem Cells: The Architects of the Tumor Ecosystem.
B. Prager (2019)
10.1007/s10549-008-0086-2
Pattern of metastatic spread in triple-negative breast cancer
R. Dent (2008)
10.1159/000430309
The Interaction Between MiR-141 and lncRNA-H19 in Regulating Cell Proliferation and Migration in Gastric Cancer
X. Zhou (2015)
10.1158/0008-5472.CAN-17-0994
The Biology of Cancer Exosomes: Insights and New Perspectives.
Carolina F. Ruivo (2017)
10.1158/0008-5472.CAN-15-1490
Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.
A. Stiff (2016)
10.1038/nrc3245
The immune contexture in human tumours: impact on clinical outcome
W. Fridman (2012)
10.1002/IJC.2910400315
MHC‐controlled susceptibility to C3H‐MTV‐induced mouse mammary tumors is predominantly systemic rather than local
A. Dux (1987)
10.3389/fimmu.2019.01767
Examining Peripheral and Tumor Cellular Immunome in Patients With Cancer
E. Holl (2019)
10.1016/j.bbcan.2017.10.007
Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents.
M. Santoni (2018)
10.1093/hmg/ddp078
FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation.
M. Udler (2009)
10.1073/pnas.1805020115
Inhibition of tumor–microenvironment interaction and tumor invasion by small-molecule allosteric inhibitor of DDR2 extracellular domain
Whitney R. Grither (2018)
10.1158/1078-0432.CCR-07-4756
Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes
C. Desmedt (2008)
10.3389/fphar.2017.00332
Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy
F. Concha-Benavente (2017)
10.1016/j.ccr.2008.06.005
Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence.
S. Ansieau (2008)
10.1158/1078-0432.CCR-15-1125
RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
S. Loi (2015)
10.1038/nm.3394
Microenvironmental regulation of tumor progression and metastasis
Daniela F. Quail (2013)
10.1016/S0140-6736(18)30789-X
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
F. Pagès (2018)
10.1016/j.biocel.2018.08.011
Role of tumor microenvironment in cancer stem cell chemoresistance and recurrence.
Madhurima Das (2018)
Immune modulatory functions of EZH2 in the tumor microenvironment: implications in cancer immunotherapy.
Xiaohai Wang (2019)
10.1002/mc.21977
Human MCS5A1 candidate breast cancer susceptibility gene FBXO10 is induced by cellular stress and correlated with lens epithelium‐derived growth factor (LEDGF)
X. Xu (2014)
10.1038/cddis.2016.403
Epigenetic regulation of HGF/Met receptor axis is critical for the outgrowth of bone metastasis from breast carcinoma
P. Bendinelli (2017)
10.1634/theoncologist.2019-0123
Disparity in Tumor Immune Microenvironment of Breast Cancer and Prognostic Impact: Asian versus Western Populations.
Ching-Hsuan Chen (2019)
10.1016/j.bpc.2019.106213
Structure-based derivation and intramolecular cyclization of peptide inhibitors from PD-1/PD-L1 complex interface as immune checkpoint blockade for breast cancer immunotherapy.
K. Zhou (2019)
10.1186/s12943-019-0975-5
Exosomes in the tumor microenvironment as mediators of cancer therapy resistance
I. Li (2019)
10.2741/S527
The persisting puzzle of racial disparity in triple negative breast cancer: looking through a new lens.
Chakravarthy Garlapati (2019)
10.1016/j.jsbmb.2019.105415
Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy
D. Márquez-Garbán (2019)
10.1186/s40425-018-0376-0
Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers
M. U. Mushtaq (2018)
10.1309/AJCPYO5FSV3UPEXS
Breast cancer subtypes predispose the site of distant metastases.
A. Soni (2015)
10.1002/path.1706
Molecular mechanisms of drug resistance
D. Longley (2005)
10.1002/jcb.27850
Evaluation of exosomal miR‐9 and miR‐155 targeting PTEN and DUSP14 in highly metastatic breast cancer and their effect on low metastatic cells
V. Kia (2019)
10.1038/s41419-017-0030-7
MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast cancer via direct targeting of STMN1
Y. Li (2017)
10.3389/fimmu.2019.01351
Lysine-Specific Histone Demethylase 1A Regulates Macrophage Polarization and Checkpoint Molecules in the Tumor Microenvironment of Triple-Negative Breast Cancer
Abel H. Y. Tan (2019)
10.1038/35077219
The Hedgehog and Wnt signalling pathways in cancer
J. Taipale (2001)
10.1084/jem.20151159
T cell metabolism drives immunity
M. D. Buck (2015)
10.2174/1389200220666190819151946
Cisplatin-resistant MDA-MB-231 cell-derived exosomes increase the resistance of recipient cells in an exosomal miR-423-5p-dependent manner.
B. Wang (2019)
10.1016/j.breast.2016.09.002
Tumor microenvironment-mediated chemoresistance in breast cancer.
Kobra Velaei (2016)
10.1038/ncomms1285
Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells
M. Mittelbrunn (2011)
10.3390/jcm8010038
FAK is Required for Tumor Metastasis-Related Fluid Microenvironment in Triple-Negative Breast Cancer
M. Pan (2019)
MicroRNA expression profile of MCF-7 human breast cancer cells and the effect of green tea polyphenon-60.
Lindsey N. Fix (2010)
10.1111/j.1600-0854.2011.01225.x
Exosome Secretion: Molecular Mechanisms and Roles in Immune Responses
Angélique Bobrie (2011)
10.1200/JCO.2010.34.5579
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.
L. Carey (2012)
10.1038/s41571-018-0050-y
Immunoscore provides a more accurate prognosis
P. Sidaway (2018)
10.1016/j.cell.2017.06.031
Exosome RNA Unshielding Couples Stromal Activation to Pattern Recognition Receptor Signaling in Cancer
Barzin Y. Nabet (2017)
10.3390/cancers11091223
Novel Biomarkers for Personalized Cancer Immunotherapy
Y. Shindo (2019)
10.1158/0008-5472.CAN-15-2770
STAT3 Establishes an Immunosuppressive Microenvironment during the Early Stages of Breast Carcinogenesis to Promote Tumor Growth and Metastasis.
L. M. Jones (2016)
10.1016/j.biomaterials.2018.10.019
In vivo β-catenin attenuation by the integrin α5-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis.
Yunfei Li (2019)
10.18632/oncotarget.23238
Breast cancer cell-derived exosomes and macrophage polarization are associated with lymph node metastasis
Y. J. Piao (2018)
10.3389/fimmu.2018.00040
Hypoxia Pathway Proteins As Central Mediators of Metabolism in the Tumor Cells and Their Microenvironment
Sundary Sormendi (2018)
10.18632/oncotarget.12658
Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer
Ken Takai (2016)
10.3389/fcell.2018.00122
mTOR Regulation of Glycolytic Metabolism in T Cells
R. Salmond (2018)
10.18632/ONCOTARGET.3591
Resistin and interleukin-6 exhibit racially-disparate expression in breast cancer patients, display molecular association and promote growth and aggressiveness of tumor cells through STAT3 activation
S. Deshmukh (2015)
10.1158/0008-5472.CAN-18-3060
Remodeling the Tumor Microenvironment Sensitizes Breast Tumors to Anti- Programmed Death-Ligand 1 Immunotherapy.
Renee T. Clift (2019)
10.1038/nature21349
Elements of cancer immunity and the cancer–immune set point
D. Chen (2017)
10.1158/1078-0432.CCR-18-2782
Impact of Breast Cancer Subtypes on Prognosis of Women with Operable Invasive Breast Cancer: A Population-based Study Using SEER Database
Ki-Tae Hwang (2018)
10.1007/s00262-017-2074-z
Quantification of altered tissue turnover in a liquid biopsy: a proposed precision medicine tool to assess chronic inflammation and desmoplasia associated with a pro-cancerous niche and response to immuno-therapeutic anti-tumor modalities
N. Willumsen (2017)
10.1016/j.clbc.2017.07.013
Alarming Burden of Triple‐Negative Breast Cancer in India
K. K. Thakur (2018)
10.1007/978-1-4939-7860-1_12
Ex Vivo Radiolabeling and In Vivo PET Imaging of T Cells Expressing Nuclear Reporter Genes.
Maxim A. Moroz (2018)
10.1158/1538-7445.AM2018-3929
Abstract 3929: The FAD-directed LSD1 specific inhibitor, INCB059872, inhibits cell migration and metastasis by suppressing premetastatic niche formation in a spontaneous metastasis mouse model
S. Lee (2018)
10.1172/JCI45014
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
B. Lehmann (2011)
10.1016/j.ejca.2013.01.017
Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells.
K. O'Brien (2013)
10.18632/oncotarget.5782
ALDH/CD44 identifies uniquely tumorigenic cancer stem cells in salivary gland mucoepidermoid carcinomas
A. Adams (2015)
10.1371/journal.pone.0203965
LDH-A regulates the tumor microenvironment via HIF-signaling and modulates the immune response
I. Serganova (2018)
10.1186/s12964-019-0325-7
Metastasis-associated protein 1 (MTA1) is transferred by exosomes and contributes to the regulation of hypoxia and estrogen signaling in breast cancer cells
Bethany N. Hannafon (2019)
10.1186/bcr2234
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
A. Rody (2008)
10.1126/science.aar4060
Cancer immunotherapy using checkpoint blockade
A. Ribas (2018)
10.2353/ajpath.2010.091125
Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome.
A. Khramtsov (2010)
10.1002/ANA.410420310
Hypoxia—ischemia causes abnormalities in glutamate transporters and death of astroglia and neurons in newborn striatum
L. Martin (1997)
10.1155/2014/179486
Exosome in Tumour Microenvironment: Overview of the Crosstalk between Normal and Cancer Cells
C. Roma-Rodrigues (2014)
Hypoxia-Inducible Factor (HIF)-1 Regulatory Pathway and its Potential for Therapeutic Intervention in Malignancy and Ischemia
Jennifer E. Ziello (2007)
10.3390/cancers10090295
Epigenetic Crosstalk between the Tumor Microenvironment and Ovarian Cancer Cells: A Therapeutic Road Less Traveled
Yuliya Klymenko (2018)
10.3389/fonc.2019.00390
The Prognostic Role of Ribosomal Protein S6 Kinase 1 Pathway in Patients With Solid Tumors: A Meta-Analysis
S. Zhang (2019)
10.21037/tcr.2017.07.09
Exosome mediated phenotypic changes in lung cancer pathophysiology.
Y. Shimada (2017)
10.2174/1871520616666160502122724
Breast Cancer: Current Molecular Therapeutic Targets and New Players.
S. Nagini (2017)
10.2217/pgs-2017-0117
Triple-negative breast cancer and the potential for targeted therapy
J. Jhan (2017)
10.3390/ijms19082453
Role of mTOR Signaling in Tumor Microenvironment: An Overview
Fabiana Conciatori (2018)
10.1186/s12885-019-5360-7
Hypoxia-induced cancer stemness acquisition is associated with CXCR4 activation by its aberrant promoter demethylation
Nahyeon Kang (2019)
10.1158/1078-0432.CCR-16-2174
Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance
Anosheh Afghahi (2017)
10.3389/fcell.2019.00086
The Role of the Extracellular Matrix in Cancer Stemness
Sameera Nallanthighal (2019)
10.21147/j.issn.1000-9604.2017.03.10
Role of tumor microenvironment in triple-negative breast cancer and its prognostic significance
Tianjian Yu (2017)
10.1016/j.bbrc.2017.02.014
SOX10 induced Nestin expression regulates cancer stem cell properties of TNBC cells.
W. Feng (2017)
10.1038/nri2567
Membrane vesicles as conveyors of immune responses
C. Théry (2009)
10.1038/ni.2703
Innate and adaptive immune cells in the tumor microenvironment
T. Gajewski (2013)
10.1016/j.biocel.2012.08.005
MiRNA expression analysis of cancer-associated fibroblasts and normal fibroblasts in breast cancer.
L. Zhao (2012)
10.3892/mmr.2018.9664
Human adipose-derived mesenchymal stem cells promote breast cancer MCF7 cell epithelial-mesenchymal transition by cross interacting with the TGF-β/Smad and PI3K/AKT signaling pathways
Simeng Wu (2019)
10.1093/annonc/mdu227
Immunoscoring breast cancer: TILs remember what they target.
G. Curigliano (2014)
10.1007/s10549-018-4925-5
Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells
P. M. M. Ozawa (2018)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar